Follicular dendritic cell secreted protein (FDC-SP) is a secreted peptide predominantly expressed in mucosal tissues. We previously reported that FDC-SP transgenic mice have altered B-cell responses to systemic immunization; however, the role of FDC-SP in mucosal immunity is unknown. Here, we report that FDC-SP functions in regulating immunoglobulin A production. FDC-SP transgenic mice show decreased IgA levels in serum, saliva, and bronchoalveolar lavage fluid. Reciprocally, FDC-SP-deficient mice show significantly increased IgA levels in serum and intestinal lavage, associated with accumulation of IgA þ cells in blood, bone marrow, Peyer's patches, and lymph nodes. FDC-SP-deficient mice generated higher titers of antigen-specific IgA but normal IgG1 responses upon immunization. Purified FDC-SP transgenic B cells generated decreased IgA responses to transforming growth factor b (TGFb) þ interleukin 5 (IL5) stimulation. Consistent with a direct effect of FDC-SP on B cells, recombinant FDC-SP suppressed B-cell IgA production in vitro. Six-to 14-month-old FDC-SP-deficient mice show IgA deposition in kidney glomeruli, which was associated with proteinuria and pathology consistent with mild IgA nephropathy (IgAN). Our results demonstrate a novel biological activity of FDC-SP in controlling B-cell IgA production and identify FDC-SP-deficient mice as a novel mouse model of IgAN.
INTRODUCTION
The follicular dendritic cell secreted protein (FDC-SP) gene encodes an 85 amino-acid secreted protein with a unique expression pattern. We previously reported that human FDC-SP is expressed within human tonsils and lymph nodes, but not spleen, gut tissues, or blood leukocytes. 1 Within tonsil, FDC-SP is expressed in germinal centers, FDCs, and also within tonsillar crypts.
1 FDC-SP expression is inducible by bacterial products such as lipopolysaccharide (LPS) or killed Staphylococcus aureus Cowan, or inflammatory stimuli such as tumor necrosis factor a.
1 While FDC-SP was identified via its expression in FDCs, it was subsequently reported to be expressed in salivary gland and periodontal ligament, 2 head and neck cancers, 3 and ovarian/breast cancers. [4] [5] [6] The fdc-sp/c4orf7 gene is located within a cluster of genes encoding small secreted proteins present in secretions including saliva and milk. 7 FDC-SP protein is present in saliva 8 and FDC-SP mRNA was recently identified by genome-wide profiling as a highly selective marker for human saliva. 9 Transgenic mice constitutively expressing mouse FDC-SP in all lymphoid tissues were found to generate reduced serum IgG2b and IgG3 responses but normal IgM and IgG1 responses after immunization; 10 however, the function of FDC-SP in mucosal immunity remains unknown.
Generation of mucosal IgA antibody in the gastrointestinal tract and other mucosal sites likely share a number of common mechanisms at the level of induction of IgA isotype switch and homing of mucosal-primed B cells. 11 A number of cytokines are implicated in IgA production including transforming growth factor b (TGFb) 12 and the tumor necrosis factor ligand family members B cell activating factor and a proliferationinducing ligand. 13 IgA responses also appear to be driven by commensal microorganisms, via both innate mechanisms such as microbial induction of IgA switch factors 14 and specific recognition of microbial antigens. [15] [16] [17] B cells primed for IgA isotype switch at mucosal inductive sites such as NALT, BALT, and GALT are programmed with specific homing receptors to promote return to mucosal sites after recirculation. 11, 18, 19 IgA-producing plasma cells can be found in many mucosal areas, including tonsil, salivary glands, nasal passage, and gut lamina propria.
Abnormal systemic IgA production can lead to IgA deposition in the kidney, resulting in IgA nephropathy (IgAN). 23, 24 Mucosal induction sites are proposed to play an important role in generating systemic IgA and IgA-related pathology; 25, 26 however, the underlying mechanisms are not understood. Clinically, IgAN frequently presents as an acute episode of kidney dysfunction (detected by hematuria and proteinuria) often closely associated with infection such as tonsillitis, pharyngitis, or ''flu'', 27 suggesting that excessive mucosal IgA responses triggered by pathogens may have a role. In some parts of Asia, tonsillectomy is routinely performed as a treatment for IgAN patients; 28 however, the efficacy of this approach has not been validated in a large controlled trial. 26 Clearly much remains to be learned about the regionally specialized mechanisms controlling IgA generation and their impact on systemic IgA levels.
In this study, we probe the function of FDC-SP in mucosal immunity using FDC-deficient and transgenic mice, focusing on oral and respiratory IgA responses. Strikingly, we find that FDC-SP deficiency and overexpression have reciprocal effects on IgA, with FDC-SP-deficient mice showing significantly elevated salivary and serum IgA, while transgenic mice show reduced levels. We further show that FDC-SP-deficient mice generate increased Ag-specific IgA responses upon immunization, show systemic accumulation of IgA þ cells, and develop IgAN-like kidney pathology. These results provide the first evidence that FDC-SP can modulate mucosal immune responses and suggest that this peptide may directly act on B cells to regulate production of IgA.
RESULTS

FDC-SP transgenic mice show suppression of IgA production
We have previously generated and characterized FDC-SP transgenic mice in terms of their Ag-specific serum IgM and IgG responses generated after immunization. 10 Given the accumulating data suggesting FDC-SP may function at mucosal surfaces we assessed IgA antibody levels in serum, saliva, and bronchoalveolar lavage fluid (BALF) from these mice. We found that FDC-SP transgenic serum had significantly reduced levels of IgA compared with controls, whereas IgG1 and IgM antibody levels were not significantly different (Figure 1a) . Saliva also showed significantly reduced IgA levels (Figure 1b) , while, in contrast, salivary IgG1 levels were significantly increased. BALF derived from FDC-SP transgenic mice also showed abnormal antibody levels, with reduced IgA but elevated IgG1 (Figure 1c) . These results suggest that overexpression of FDC-SP can suppress IgA production and deregulate IgG1 production in oral and respiratory fluids. Figure S2A) . The major lymphoid and myeloid cell subsets were present at normal frequencies (Supplementary Figure S2B) . Serum, saliva, and BALF were collected from young adult mice and levels of antibody isotypes were assessed ( Figure 2) . FDC-SP-deficient mice showed significantly elevated levels of all Ig isotypes examined in serum, while saliva and BALF showed increased levels of IgA and IgG1. We further examined generation of antigen-specific IgA upon immunization with 4-hydroxy-3-nitrophenyl-ovalbumin þ LPS and found that FDC-SP-deficient mice generated significantly higher titers of anti-NP IgA than controls, whereas anti-NP IgG1 titers were not significantly different ( Figure 3) . We assessed the frequencies of IgA þ B cells in various tissues of FDC-SP-deficient mice and found striking, variable increases in IgA þ cells in blood, cervical lymph nodes, and bone marrow, whereas IgG1 þ cells were not significantly increased (Figure 4a,b) . These IgA þ cells were largely B220 þ and CD138 lo , consistent with an abnormal accumulation of IgA-switched pre-plasma cells; however, increased populations of B220 lo , CD138 þ and intracellular IgA þ plasma cells could also be observed in bone marrow (Figure 4c) . However, the proportion of IgA þ cells bearing an intracellular-IgA hi / CD138 þ phenotype was not increased in FDC-SP-deficient mice (Figure 4d) , suggesting that differentiation of IgAswitched cells into plasma cells is not affected. Together, these data indicate that FDC-SP deficiency leads to deregulated generation of IgA þ B cells and has a reciprocal effect on IgA levels relative to FDC-SP transgenic mice. Although FDC-SP expression has not been prominently observed in the gastrointestinal tract, [1] [2] [3] it is possible that swallowed salivary peptides (or fragments thereof) may reach the gut, or influence the gut through other indirect mechanisms of communication between mucosal sites. We examined IgA levels present in intestinal lavage and found that they were significantly increased, whereas IgM levels were normal (Figure 5a 
FDC-SP can regulate IgA production in vitro
To determine whether FDC-SP can directly regulate B-cell production of IgA, we utilized established protocols to induce IgA production in vitro. 29 Purified IgA-negative B cells isolated from control or FDC-SP transgenic mice were isolated, cultured with or without TGFb, and then assessed for generation of IgA with control supernatants, whereas IgM levels were not affected ( Figure 6c) . Together, these results indicate that FDC-SP can act directly on B cells to influence IgA production.
FDC-SP knockout mice develop nephropathy with age
Chronic elevation of IgA levels is associated with kidney dysfunction in the disease IgA nephropathy (IgAN). To determine whether chronically elevated IgA levels in FDC-SP-deficient mice may impact on kidney function, we examined FDC-SP-deficient mice at 6-14 months of age. In aged mice, IgA levels remained elevated, whereas IgG1 levels normalized relative to a matched control cohort (Figure 7a) . We examined kidney sections by light microscopy and found that FDC-SP glomeruli show variable mild mesangial cell proliferation (Figure 7b, top panels) . Staining for IgA, IgG, and complement C3 revealed immune complex deposition in glomeruli of FDC-SP-deficient mice, but not in control mice (Figure 7b , middle panels). Examination by electron microscopy revealed electron dense deposits in mesangial extracellular matrix, Serum, saliva, and bronchoalveolar lavage fluid (BALF) were collected from mice at 6-14 months of age and serum IgA and IgG1 levels were determined. Note IgA levels remain elevated but, unlike young mice, IgG1 levels were not significantly different. (b) Kidney pathology analyses. Formalin-fixed sections were assessed by hematoxylin eosin (H&E) staining and imaged under Â 600 magnification (top panels). Kidney cryosections were collected, stained with anti-IgA, anti-IgG, or anti-C3 antibodies and imaged under Â 1,000 magnification (middle panels). Glutaraldehyde-fixed sections were examined under Â 10,000 magnification by electron microscopy (EM) (bottom panels). Relative magnification is indicated. Examples of electron-dense mesangial immune complex-type deposits in FDC-SP-deficient kidneys are indicated by white arrows. Results are representative of four FDC-SP knockout (KO) mice examined by immunofluorescence and light microscopy and two FDC-SP KO mice examined by EM. (c) Urine and serum analyses. 24-h urine collections were taken from 6-to 8-month-old FDC-SP-deficient or control mice and total protein excretion was measured (top panel). Presence of red blood cells in urine samples was determined by urinalysis dipstick test (middle panel). Serum creatinine levels were determined in a cohort of 14-month-old mice (bottom panel). WT, wild type; PC, plasma cell. consistent with mesangial immune complex deposition (Figure 7b , bottom panels). Urinalysis indicated variable hematuria, increased 24-h protein excretion, and slight elevation in serum creatinine in 8-to 14-month-old FDC-SP-deficient mice (Figure 7c) , consistent with development of chronic kidney dysfunction. Interestingly, IgA levels were most consistently elevated in male FDC-SP-deficient mice and only male mice showed significantly increased protein excretion (Supplementary Figure S3) . These data indicate that FDC-SP deficiency leads to chronic elevation of IgA, deposition of IgA in kidney glomeruli and kidney dysfunction with a male bias, similar to human IgAN.
DISCUSSION
This is the first report identifying a function of FDC-SP in mucosal immunity. Our results demonstrate that FDC-SP can directly regulate IgA production and that the absence of FDC-SP leads to deregulation of IgA. The restricted expression of FDC-SP within cervical lymph node, salivary gland, periodontal ligament, and oral-associated lymphoid tissue suggests that FDC-SP provides region-specific control of IgA homeostasis. We have previously found that FDC-SP expression can be induced by microbial products and inflammatory stimuli, suggesting that it may serve as an endogenous brake on IgA responses induced by pathogenic or commensal microorganisms in oral/respiratory mucosa.
FDC-SP transgenic mice show strongly inhibited IgA levels but relatively normal IgG and IgM levels, consistent with a relatively selective effect on IgA. Young adult FDC-SP-deficient mice were found to have elevated IgM, IgG, and IgA levels, possibly suggesting a global deregulation of natural antibody production. However, by 6 months of age IgM and IgG levels were found to be similar to control mice, while IgA levels remained elevated. Immunization studies indicated that FDC-SP knockout (KO) mice generated significantly higher titers of antigen-specific IgA, while generation of Ag-specific IgM and IgG were relatively normal. While we cannot rule out other immunological defects in these mice, the current data strongly indicate that a selective effect of FDC-SP on generation of IgAexpressing B cells is one of the activities of this peptide.
Elevated numbers of IgA þ B cells were found in cervical lymph nodes, blood, and bone marrow of FDC-SP-deficient mice. The presence of significant numbers of IgA þ cells in blood is intriguing and suggests potential spill-over of IgAswitched B cells from mucosal sites. Marginally elevated frequencies of IgA þ B cells were also observed in gut-associated lymphoid tissues, significantly impacting on gut IgA levels. Since FDC-SP is mainly expressed at oral and respiratory sites, these results may indicate that swallowed salivary FDC-SP can influence the gut. Alternatively, FDC-SP may indirectly affect gut IgA production via modulation of microbiota or via other systemic effects. IgA þ cells did not accumulate in spleen, consistent with lack of FDC-SP expression in spleen and selective homing of mucosal-primed B cells to mucosal sites. þ plasma cells were found in bone marrow and Peyer's patches, the proportion of IgA þ cells expressing a plasma cell phenotype was not significantly higher in FDC-SP-deficient mice. This result argues against a role for FDC-SP in promoting differentiation of IgA-switched cells into plasma cells. In vitro studies with purified B cells supported a direct effect of FDC-SP on induction of both surface IgA þ and IgA-secreting cells, perhaps acting at the level of isotype switch. Since FDC-SP was found to bind selectively to B cells, 1 the simplest hypothesis is that an FDC-SP-binding receptor can transduce signals inhibiting IgA isotype switch. We previously also found evidence that FDC-SP could influence migration of activated B cells, 1 thus another possibility is that FDC-SP deficiency could impact tissue homing of IgA þ B cells. We hypothesize that the FDC-SP gene gives rise to multiple processed peptides with multiple immune-modulatory functions, analogous to other immune-modulatory secreted peptides expressed at mucosal surfaces and in saliva, [30] [31] [32] but has a non-redundant function impacting IgA production.
FDC-SP-deficient mice have a phenotype with several similarities to human IgAN, including chronic elevation of IgA, deposition of IgA immune complexes in kidney, and kidney dysfunction. Relatively mild kidney pathology is a feature of many cases of IgAN, and the disease is often undetected until routine urinalysis reveals proteinuria or hematuria. 23, 24 Human IgAN is more frequent in males, consistent with findings in FDC-SP KO mice. Interestingly, human IgAN is frequently associated with respiratory infections that may provoke episodes of hyper-IgA production leading to acute kidney dysfunction. 27, 33 IgAN patients have been shown to have abnormal numbers of IgA þ cells in tonsils 34 and abnormal response to mucosal immune challenge. 35 Tonsillectomy is a routine intervention for IgAN in Japan, intended to dampen mucosal IgA production; 28 however, the efficacy of this approach has not been proven by a large-scale trial. Given the evidence that abnormal mucosal immune responses are associated with IgAN, it will be interesting to examine responses to oral or respiratory pathogens in FDC-SP-deficient mice and determine whether they exacerbate IgAN-like pathology.
A few other mouse models of IgAN have been described, including the ddY mouse and B cell activating factor transgenic mice. 36 B cell activating factor transgenic mice produce a more severe, acute form of IgAN with very large elevation of IgA and IgG and significant kidney pathology affect both males and females. 25, 37 The ddY mouse exhibits spontaneous glomerular IgA deposition and provides a multigenic disease model. 38, 39 The original ddY model was not consistently associated with elevated IgA levels, but a variant of the strain with hyper-IgA and accelerated disease progression was recently described. 40 On the basis of the results here, FDC-SP-deficient mice provide a novel single-gene deficiency model on a defined genetic background with potential utility for studying a biological process with relevance to IgAN, namely mucosal induction of IgA responses. It should be noted that, as is the case with other mouse models, FDC-SP-deficient mice cannot recapitulate all aspects of human IgAN pathology. For example, mouse IgA is not structurally equivalent to human IgA1 and thus is unlikely to precisely mimic altered glycosylation patterns seen in this molecule that are thought to contribute to IgAN pathogenesis. 41 In summary, this study provides the first evidence supporting a function of FDC-SP in mucosal immunity. Genetic overexpression and deficiency of FDC-SP have reciprocal effects on IgA levels and this peptide can directly inhibit B-cell IgA production in vitro, together providing strong evidence implicating FDC-SP as a new regulator of IgA synthesis. While further studies will be required to delineate the molecular and cellular mechanisms by which FDC-SP controls IgA responses, the FDC-SP-deficient mouse has clear potential as a model of IgAN.
METHODS FDC-SP-deficient and transgenic mice. FDC-SP transgenic CD1 mice were generated as described. 10 FDC-SP-deficient mice were generated as illustrated in Supplementary Figure S1 . Heterozygous mice bearing the targeted collapsed FDC-SP locus were generated by crossing with Cre transgenic and homozygous FDC-SP-deficient mice were generated by subsequent back-crossing to C57BL6 for seven generations. Mice were genotyped using DNA extracted from ear punches, using the following primers:
Wild-type allele (430 bp product): GGGATAAAGTGATAAAAACGAATAGCCA and ACGGAAATCCAGAAGATGCAAGCCT KO allele (522 bp product): GGGATAAAGTGATAAAAACGAATAGCCA and GGGGCCACCAAAGAACGGAGCCGGTT All experimental animals were housed at the Central Animal Care Facility (University of Manitoba, Winnipeg, Manitoba, Canada) in compliance with the guidelines established by the Canadian Council on Animal Care. CD1 and C57BL6 control mice were bred separately within same animal facility as the FDC-SP transgenic and FDC-SPdeficient mice.
Flow-cytometry analyses. Single-cell suspensions were generated from the indicated tissues and were pre-incubated with 2.4G2 antibody to block Fc receptors. The indicated conjugated antibodies were added from the following panel: V500-labeled anti-CD4, PE anti-CD5, FITC anti-CD11b, FITC anti-CD21, PE anti-CD23, PerCP anti-CD45R/ B220, FITC anti-CD45/B220, PE anti-CD43, PE anti-Gr1, APC anti-CD183, APC anti-IgM and FITC-anti-IgG1 (all from BD Biosciences, San Jose, CA), Pacific Blue anti-CD8, AlexaFluor647 anti-mouse CD4, and PE anti-mouse IgA (eBioscience, San Diego, CA). For intracellular staining, cells were first stained with PerCP-anti-B220, APC anti-CD138, and LIVE/DEAD Aqua fixable dead cell stain (Invitrogen, Carlsbad, CA), then fixed and permeabilized using CytofixCytoperm solution (BD Biosciences) and finally intracellularly stained with PEanti-IgA. Stained cells were washed and acquired on a FACS Canto II flow cytometer (BD Biosciences). Data were analyzed using the FlowJo software (TreeStar, Ashland, OR).
Immunization and antibody measurements. Serum, saliva, BALF, and gut lavage 42 fluids were collected from 10-to 14-week-old FDC-SP-deficient mice, FDC-SP transgenic mice and strain, age and sexmatched controls. Where indicated mice were immunized intraperitoneally with 4-hydroxy-3-nitrophenyl-ovalbumin, alum, and LPS. For ELISAs, 96-well assay plates were coated overnight at 4 1C with capture antibodies or antigen diluted in carbonate coating buffer (0.015 M Na 2 CO 3 , 0.035 M NaHCO 3 , 0.05% NaN 3 , pH 9.6). Total antibody levels were determined by coating with anti-mouse IgM, IgG1, or IgA (Jackson ImmunoResearch Laboratories, West Grove, PA) or NP-specific antibody levels were determined by coating plates with NP20-BSA (Biosearch Technologies, Petaluma, CA). Detection was carried out using biotinylated anti-mouse IgM, IgG1, or IgA antibodies (Southern Biotechnology, Birmingham, AL) followed by streptavidin alkaline phosphatase.
B-cell isolation and cultures. Mouse splenocytes were collected and B cells were purified by negative selection with the CD43 MicroBeads and MACS columns (Miltenyi Biotech, Bergisch Gladbach, Germany). Purified B cells were incubated in dishes coated with goat anti-mouse IgA (4 mg ml À 1 ) for 70 min at 4 1C, resulting in 495% depletion of sIgA þ cells. IgA-depleted B cells were then washed and resuspended in complete medium (Opti-MEM containing penicillin-streptomycin, 2-mercaptoethanol and 10% FBS). A total of 4 Â 10 5 cells per well were cultured in flat-bottomed, 96-well tissue-culture plates in a volume of 100 ml complete medium containing 10 mg ml À 1 LPS (Escherichia coli 0127:B8; Sigma Chemical, St Louis, MO), 100 U ml À 1 murine interleukin 5 (IL5) (R&D Systems, Minneapolis, MN), and 1 ng ml
TGFb1 (R&D Systems). After 5 days of culture, supernatants were harvested for ELISA analysis and cells for flow cytometry. FDC-SP containing L cell supernatants were generated from stable transfectants as described. 10 Serum-free supernatants were prepared by extensively washing and culturing confluent L cells in medium containing 0.5% BSA for overnight. Supernatants were harvested and used immediately or aliquoted and stored frozen at -80 1C.
Urine and kidney analyses. Kidneys were harvested and either embedded in O.C.T. compound (Tissue Tek, Tokyo, Japan) and snap frozen using liquid nitrogen for cryosectioning, 10% formalin fixed for light microscopy or 2% glutaraldehyde fixed for electron microscopy. Cryosections were cut at 8 mm using a cryostat and placed onto slides (Fisherbrand Superfrost/Plus, Waltham, MA). Frozen sections were fixed for 15-20 min using ice-cold acetone, blocked with 10% normal goat serum for 1 h and stained with either FITC anti-IgA or anti-IgG (Southern Biotechnology). Complement deposition was detected by staining with anti-C3 antibody (Abcam, Cambridge, UK, #ab11862) followed by Alexa 488-goat anti-rat IgG (Abcam #ab150157). After mounting, sections were imaged using a confocal microscope (Ultraview LCI, Perkin-Elmer, Waltham, MA). For pathology analyses, formalin-fixed kidneys were paraffin embedded, sectioned and stained with hematoxylin and eosin stain; glutaraldehyde-fixed kidney samples were embedded in resin and ultrasectioned for examination with electron microscopy. For 24 h urine protein assay, individual mice were put in a metabolic cage with water but no food for 24 h. Collected urine was clarified by centrifugation at 3,000 r.p.m. and protein measured using Bradford protein assay (Bio-Rad, Hercules, CA). Total protein was determined by multiplying protein concentration by volume and was independently measured three times per animal.
SUPPLEMENTARY MATERIAL is linked to the online version of the paper at http://www.nature.com/mi
